Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal, and higher sensitivity to the drug. (11th April 2020)

• Record Type: Journal Article
• Authors: Girard, Pierre‐Marie; Berthault, Nathalie; Kozlac, Maria; Ferreira, Sofia; Jdey, Wael; Bhaskara, Srividya; Alekseev, Sergey; Thomas, Frederic; Dutreix, Marie
• Other Names: Thomas Frédéric guestEditor.; Giraudeau Mathieu guestEditor.; Hamede Rodrigo guestEditor.; Roche Benjamin guestEditor.; Ujvari Beata guestEditor.
• Is Part Of: Evolutionary applications. Volume 13:Number 7(2020)
• Page Start: 1673
• Page End: 1680
• Publication Date: 2020-04-11
• Subjects: biomedicine -- disease biology -- evolutionary theory -- transcriptomics; Evolution (Biology) -- Periodicals; Genetics -- Periodicals; Natural selection -- Periodicals; Ecology -- Periodicals; 576.8
• DOI: 10.1111/eva.12949
• Languages: English
• ISSNs: 1752-4571

Abstract

Abstract: It is increasingly suggested that ecological and evolutionary sciences could inspire novel therapies against cancer but medical evidence of this remains scarce at the moment. The Achilles heel of conventional and targeted anticancer treatments is intrinsic or acquired resistance following Darwinian selection; that is, treatment toxicity places the surviving cells under intense evolutionary selective pressure to develop resistance. Here, we review a set of data that demonstrate that Darwinian principles derived from the "smoke detector" principle can instead drive the evolution of malignant cells toward a different trajectory. Specifically, long‐term exposure of cancer cells to a strong alarm signal, generated by the DNA repair inhibitor AsiDNA, induces a stable new state characterized by a down‐regulation of the targeted pathways and does not generate resistant clones. This property is due to the original mechanism of action of AsiDNA, which acts by overactivating a "false" signaling of DNA damage through DNA‐PK and PARP enzymes, and is not observed with classical DNA repair inhibitors such as the PARP inhibitors. Long‐term treatment with AsiDNA induces a new "alarm down" state in the tumor cells with decrease in NAD level and reactiveness to it. These results suggest that agonist drugs such as AsiDNA could promote a state‐dependent tumor cell evolution by lowering their ability to respond to high "danger" signal. This analysis provides a compelling argument that evolutionary ecology could help drug design development in overcoming fundamental limitation of novel therapies against cancer due to the modification of the targeted tumor cell population during treatment.